+1-518-621-2074 | US-Canada Toll Free Contact Us

Growing Prevalence of Diabetes and Obesity to Drive Drug Development

about us

Published on : Dec 05, 2016

ALBANY, NY, Dec 05, 2016: The report analyzes the current and historical state of the drug development pipeline for diabetes and obesity. The study discusses key factors influencing the drug development for obesity and diabetes such as growth drivers and market challenges. It also throws light upon the impact of these drivers and challenges. Further, it analyzes the impact of the various regulations laid by government and other regulatory bodies. Thus, the report is expected to help investors in making smart and wise decisions regarding investments in the drug development for diabetes and obesity. The trends and growth opportunities in this field have been elaborated.

Experts and market professionals have collated a report that comprises fruitful information which is depicted by charts, tables, statistics, figures, and graphs. A detailed analysis of key companies and their recent drug developments have been given. Important information regarding their mergers, collaborations, acquisitions, partnerships and joint ventures in their attempt to develop effective drugs for the treatment of diabetes and obesity has been given in detail. The report discusses the extent to which institutions and universities play a role in the pipeline as compared to pharmaceutical companies.

Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=877732

As the prevalence of diabetes among people are increasing, it is becoming increasingly necessary to have a more efficacious drug or treatment method. Diabetes and obesity disease cluster is presently led by therapeutics for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) and a majority of the drug development pipeline is for these indications as compared to drugs indicated for obesity. This is because, drugs indicated for obesity do not have a large market presence. However, there are a large number of products indicated for obesity in the pipeline and most of these products are still in their early stages of development. Thus, overall, the joint therapy of diabetes and obesity presents a strong pipeline and represents a significant proportion of the overall metabolic disorders therapy area. 

Most of the products in the market are biologics and small molecules and these are reflecting on the pharma co-therapeutic trend.  The report assesses the products, which are under development in detail and also offers an overview of each pipeline program for every indication. The recent updates and milestones achieved by each of the pipeline program are discussed in the report. It also gives information regarding the companies, universities, and institutions that are presently operating in the pipeline. The study helps with a better understanding of the composition of the pipeline in terms of molecule type, target, route of administration, and mechanism of action. 

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]